Meta-hlorofenilpiperazin

Из Википедије, слободне енциклопедије
meta-Hlorofenilpiperazin
MCPP.svg
MCPP3d.png
IUPAC ime
1-(3-hlorofenil)piperazin
Klinički podaci
Način primene Oralno, nazalno, rektalno
Farmakokinetički podaci
Metabolizam Hepatic
Poluvreme eliminacije 2-6 sata
Izlučivanje Renalno
Identifikatori
CAS broj 6640-24-0 ДаY
ATC kod none
PubChem CID 1355
IUPHAR/BPS 142
ChemSpider 1314 ДаY
ChEBI CHEBI:10588 ДаY
ChEMBL CHEMBL478 ДаY
Hemijski podaci
Formula C10H13ClN2
Molarna masa 196,676 g/mol
  (verify)

meta-Hlorofenilpiperazin (mCPP) je psihoaktivni lek iz fenilpiperazinske klase. On je razvijen krajem 1970-tih i korišten je u naučnim istraživanjima, pre nego što je postao dezijnirana droga sredinom 2000-tih.[1][2] mCPP je detektovan u pilulama koje su reklamirane kao legalne alternative za nedopuštne stimulanse u Novom Zelandu i u pilulama koje su prodavane kao "ekstazi" u Evropi i Sjedinjenim Državama.[3][4]

Uprkos pokušaja da se uvede u upotrebu kao rekreaciona supstanca, mCPP se zapravo generalno smatra nepoželjnim jer proizvodi neprijatna iskustva.[3] Njemu nedostaju potkrepljujući efekti,[5] proizvodi depresivne i anksiogene efekte kod glodara i ljudi,[6][7] i može da indukuje panične napade kod osoba koje su im podložne.[8][9][10][11] On takođe pogoršava opsesivno-kompulzivne simptome kod ljudi sa tim poremećajem.[12][13][14]

Vidi još[уреди]

References[уреди]

  1. Bossong MG, Van Dijk JP, Niesink RJ (2005). „Methylone and mCPP, two new drugs of abuse?”. Addiction Biology. 10 (4): 321—3. doi:10.1080/13556210500350794. PMID 16318952. 
  2. Lecompte Y, Evrard I, Arditti J (2006). „[Metachlorophenylpiperazine (mCPP): a new designer drug]”. Thérapie (на језику: French). 61 (6): 523—30. PMID 17348609. 
  3. 3,0 3,1 Bossong M; Brunt T; Van Dijk J; et al. (2009). „mCPP: an undesired addition to the ecstasy market”. Journal of Psychopharmacology (Oxford, England). 24 (9): 1395—401. doi:10.1177/0269881109102541. PMID 19304863. 
  4. Vogels N, Brunt TM, Rigter S, van Dijk P, Vervaeke H, Niesink RJ (2009). „Content of ecstasy in the Netherlands: 1993-2008”. Addiction (Abingdon, England). 104 (12): 2057—66. doi:10.1111/j.1360-0443.2009.02707.x. PMID 19804461. 
  5. Tancer M, Johanson CE (2003). „Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP”. Drug and Alcohol Dependence. 72 (1): 33—44. doi:10.1016/S0376-8716(03)00172-8. PMID 14563541. 
  6. Rajkumar R, Pandey DK, Mahesh R, Radha R (2009). „1-(m-Chlorophenyl)piperazine induces depressogenic-like behaviour in rodents by stimulating the neuronal 5-HT(2A) receptors: proposal of a modified rodent antidepressant assay”. European Journal of Pharmacology. 608 (1-3): 32—41. doi:10.1016/j.ejphar.2009.02.041. PMID 19269287. 
  7. Kennett GA, Whitton P, Shah K, Curzon G (1989). „Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists”. European Journal of Pharmacology. 164 (3): 445—54. doi:10.1016/0014-2999(89)90252-5. PMID 2767117. 
  8. Klein E, Zohar J, Geraci MF, Murphy DL, Uhde TW (1991). „Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine's anxiogenic effects”. Biological Psychiatry. 30 (10): 973—84. doi:10.1016/0006-3223(91)90119-7. PMID 1756202. 
  9. Charney DS, Woods SW, Goodman WK, Heninger GR (1987). „Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects”. Psychopharmacology. 92 (1): 14—24. PMID 3110824. 
  10. Van Veen JF, Van der Wee NJ, Fiselier J, Van Vliet IM, Westenberg HG (2007). „Behavioural effects of rapid intravenous administration of meta-chlorophenylpiperazine (m-CPP) in patients with generalized social anxiety disorder, panic disorder and healthy controls”. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 17 (10): 637—42. doi:10.1016/j.euroneuro.2007.03.005. PMID 17481859. 
  11. van der Wee NJ, Fiselier J, van Megen HJ, Westenberg HG (2004). „Behavioural effects of rapid intravenous administration of meta-chlorophenylpiperazine in patients with panic disorder and controls”. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 14 (5): 413—7. doi:10.1016/j.euroneuro.2004.01.001. PMID 15336303. 
  12. Hollander E; DeCaria CM; Nitescu A; et al. (1992). „Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers”. Archives of General Psychiatry. 49 (1): 21—8. PMID 1728249. 
  13. Broocks A; Pigott TA; Hill JL; et al. (1998). „Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results”. Psychiatry Research. 79 (1): 11—20. doi:10.1016/S0165-1781(98)00029-8. PMID 9676822. 
  14. Pigott TA; Zohar J; Hill JL; et al. (1991). „Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder”. Biological Psychiatry. 29 (5): 418—26. doi:10.1016/0006-3223(91)90264-M. PMID 2018816. 

Spoljašnje veze[уреди]